Compare MYFW & LCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MYFW | LCTX |
|---|---|---|
| Founded | 2002 | 1990 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 312.1M | 255.4M |
| IPO Year | 2018 | 1996 |
| Metric | MYFW | LCTX |
|---|---|---|
| Price | $30.92 | $1.00 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | ★ $27.00 | $6.25 |
| AVG Volume (30 Days) | 37.2K | ★ 1.1M |
| Earning Date | 04-23-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 54.02 | N/A |
| EPS | ★ 1.20 | N/A |
| Revenue | ★ $96,914,000.00 | $14,556,000.00 |
| Revenue This Year | $20.48 | $109.40 |
| Revenue Next Year | $9.70 | N/A |
| P/E Ratio | $25.48 | ★ N/A |
| Revenue Growth | 7.60 | ★ 53.24 |
| 52 Week Low | $21.96 | $0.91 |
| 52 Week High | $34.36 | $2.09 |
| Indicator | MYFW | LCTX |
|---|---|---|
| Relative Strength Index (RSI) | 47.59 | 43.77 |
| Support Level | $30.06 | N/A |
| Resistance Level | $31.24 | $1.18 |
| Average True Range (ATR) | 0.73 | 0.06 |
| MACD | 0.01 | -0.01 |
| Stochastic Oscillator | 23.16 | 37.98 |
First Western Financial Inc is a financial holding company that provides a fully integrated suite of wealth management services on its private trust bank platform, which includes a comprehensive selection of deposit, loan, trust, wealth planning, and investment management products and services. The company has two operating segments; The Wealth Management segment consists of operations relative to the Company's fully integrated wealth management products and services, and The Mortgage segment consists of operations relative to the Company's residential mortgage service offerings. The bank derives its majority revenue from the wealth management segment.
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline currently includes: OpRegen, OPC1, ReSonance, ILT1, RND1, PNC1, and LCT-CON. Its programs are based on its proprietary, in-house, cell-based manufacturing platform, which it call AlloSCOPE (Allogeneic, Scalable, Consistent, Off-the-shelf, Pluripotent Cell Engineering), and supported by its associated development, formulation, manufacturing, and delivery capabilities. The AlloSCOPE platform is a proprietary differentiation and production modality from which, a single, well-characterized pluripotent cell line can create a stable current Good Manufacturing Practice, master cell bank.